Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Table 2

Glycemic variability between the CSII and CSII + Sig groups after the suspension of continuous subcutaneous insulin infusion.

Characteristic	Group		value
	CSII	CSII + Sig
MAGE (mmol/L)	3.98 ± 0.55	2.84 ± 0.92	<0.01
SDBG (mmol/L)	2.01 ± 0.37	1.42 ± 0.37	<0.01
LAGE (mmol/L)	6.81 ± 1.29	5.55 ± 1.27	<0.01
MBG (mmol/L)	7.95 ± 0.57	6.64 ± 0.37	<0.01
PT10.0 (%)	6.25 ± 1.48	1.50 ± 1.83	<0.01
PT3.9 (%)	2.42 ± 3.60	0.29 ± 0.73	0.04
1 h MBG
Before breakfast (mmol/L)	6.42 ± 0.45	6.04 ± 0.68	0.01
Before lunch (mmol/L)	6.68 ± 1.03	6.16 ± 0.66	0.02
Before supper (mmol/L)	6.71 ± 0.89	6.17 ± 0.56	0.01
3 h MBG
After breakfast (mmol/L)	9.78 ± 1.60	7.51 ± 0.64	<0.01
After lunch (mmol/L)	8.78 ± 1.49	7.59 ± 0.56	<0.01
After supper (mmol/L)	9.29 ± 1.78	7.50 ± 0.61	<0.01

Note: MAGE: mean amplitude of glycemic excursions; SDBG: standard deviation of blood glucose; LAGE: largest amplitude of glycemic excursions; MBG: mean blood glucose; PT3.9: proportion (%) of time in hypoglycemia (<3.9 mmol/L); PT10.0: proportion (%) of time in hyperglycemia (>10 mmol/L). Independent-samples -tests were employed.